Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT-209: Pemigatinib in FGFR-Altered Glioblastoma and Other CNS Tumors
jRCT2031220352Phase 2Suspended
- Sponsor
- Incyte
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of pemigatinib in glioblastoma (GBM), diffuse midline glioma (DMG), glioma and 4 more (2 cohorts), sponsored by Incyte. Primary endpoint: Overall Response Rate (ORR) - Cohort A. Started Oct 2022; status: suspended.
02
Drugs
pemigatinib
03
Conditions
glioblastoma (GBM)diffuse midline glioma (DMG)gliomaastrocytomaGlioneuronal Neoplasm
Beyond the preview
Go deeper on jRCT2031220352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220352.